Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-caed-2_20-cv-00425/USCOURTS-caed-2_20-cv-00425-0/pdf.json

Nature of Suit Code: 367
Nature of Suit: TORTS - Personal Injury - Health Care/Pharmaceutical Personal Injury/Product Liability
Cause of Action: 28:1332 Diversity-Product Liability

---

UNITED STATES JUDICIAL PANEL

on

MULTIDISTRICT LITIGATION

IN RE: ZANTAC (RANITIDINE) PRODUCTS

LIABILITY LITIGATION MDL No. 2924

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO í5)

On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for

the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to 28

U.S.C. § 1407. See _F.Supp.3d_ (J.P.M.L. 2020). Since that time, 86 additional action(s) have been

transferred to the Southern District of Florida. With the consent of that court, all such actions have

been assigned to the Honorable Robin L. Rosenberg.

It appears that the action(s) on this conditional transfer order involve questions of fact that are

common to the actions previously transferred to the Southern District of Florida and assigned to

Judge Rosenberg.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict

Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the

Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the

consent of that court, assigned to the Honorable Robin L. Rosenberg.

This order does not become effective until it is filed in the Office of the Clerk of the United States

District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be

stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the

Panel within this 7íday period, the stay will be continued until further order of the Panel.

FOR THE PANEL:

John W. Nichols

Clerk of the Panel

Maria Cruz Mar 18, 2020

Case 2:20-cv-00425-KJM-CKD Document 4 Filed 03/18/20 Page 1 of 3
IN RE: ZANTAC (RANITIDINE) PRODUCTS

LIABILITY LITIGATION MDL No. 2924

SCHEDULE CTOí5 í TAGíALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

ALABAMA MIDDLE

ALM 2 20í00153 Day v. Boehringer Ingelheim Pharmaceuticals, Inc. et al

ALABAMA NORTHERN

ALN 1 20í00284 Griffith v. Boehringer Ingelheim Pharmaceuticals Inc et

al

ALN 2 20í00282 Cagle v. Boehringer Ingelheim Pharmaceuticals Inc et al

ALN 4 20í00283 Walker v. Boehringer Ingelheim Pharmaceuticals Inc et

al

ALN 5 20í00280 Glasscock v. Boehringer Ingelheim Pharmaceuticals Inc

et al

ALABAMA SOUTHERN

ALS 1 20í00114 Kidd v. Boehringer Ingelheim Pharmaceuticals, Inc. et

al

ALS 2 20í00115 Martin v. Boehringer Ingelheim Pharmaceuticals, Inc. et

al

CALIFORNIA EASTERN

CAE 2 20í00425 Faltersack v. Boehringer Ingelheim Pharmaceuticals,

Inc. et al

FLORIDA MIDDLE

FLM 6 20í00384 Barnette v. Boehringer Ingelheim Pharmaceuticals, Inc.

et al

FLORIDA NORTHERN

FLN 3 20í03586 MITCHELL v. BOEHRINGER INGELHEIM

PHARMACEUTICALS INC et al

GEORGIA MIDDLE

Case 2:20-cv-00425-KJM-CKD Document 4 Filed 03/18/20 Page 2 of 3
GAM 5 20í00081 BRANTLEY v. BOEHRINGER INGELHEIM

PHARMACEUTICALS INC et al

GAM 5 20í00082 IANNUZZI v. BOEHRINGER INGELHEIM

PHARMACEUTICALS INC et al

GAM 5 20í00084 SIMMONS v. BOEHRINGER INGELHEIM

PHARMACEUTICALS INC et al

GEORGIA NORTHERN

GAN 2 20í00056 Serviss v. Boehringer Ingelheim Pharmaceuticals, Inc. et

al

KENTUCKY EASTERN

KYE 5 20í00086 Sherbet v. Boehringer Ingelheim Pharmaceuticals, Inc.

et al

TENNESSEE EASTERN

TNE 2 20í00037 McCandless v. Boehringer Ingelheim Pharmaceuticals,

Inc. et al (JRG2)

TENNESSEE WESTERN

TNW 2 20í02141 Allen v. Boehringer Ingelheim Pharmaceuticals, Inc., et

al.

TEXAS SOUTHERN

TXS 6 20í00010 Cook v. Boehringer Ingelheim Pharmaceuticals, Inc et al

Case 2:20-cv-00425-KJM-CKD Document 4 Filed 03/18/20 Page 3 of 3